Cost of Goods Sold (Annual)

Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.

West Pharmaceutical Services, Inc. (WST) had Cost of Goods Sold of $1.97B for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$3.07B
Net Income	$493.70M
Cost of Goods Sold	$1.97B
Gross Profit	$1.10B
Operating Expenses	$2.49B
Operating Income	$584.90M
Non-Operating Income/Expense	$16.00M
Pre-Tax Income	$600.90M
Normalized Pre-Tax Income	$600.90M
Income after Taxes	$479.30M
Income from Continuous Operations	$493.70M
Consolidated Net Income/Loss	$493.70M
Normalized Income after Taxes	$479.30M
EBIT	$584.90M
EBITDA	$756.30M
Weighted-Average Shares Outstanding (Basic)	72.30M
Weighted-Average Shares Outstanding (Diluted)	72.70M
Earnings per Share (EPS) (Basic)	$6.83
Earnings per Share (EPS) (Diluted)	$6.79
Balance Sheet Financials
Current Assets	$1.98B
Property, Plant, and Equipment	$1.73B
Long-Term Assets	$2.29B
Total Assets	$4.27B
Current Liabilities	$654.90M
Long-Term Debt	$202.80M
Long-Term Liabilities	$439.10M
Total Liabilities	$1.09B
Common Equity	$3.18B
Tangible Shareholders Equity	$3.06B
Shareholders Equity	$3.18B
Common Shares Outstanding	72.00M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$754.80M
Cash Flow from Investing Activities	$-285.90M
Cash Flow from Financial Activities	$-185.10M
Beginning Cash	$484.60M
End Cash	$791.30M
Increase/Decrease in Cash	$306.70M
Stock-Based Compensation	$23.80M
Common Stock Dividends Paid	$-61.20M
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	3.02
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.06
Debt to Equity Ratio	0.06
Gross Margin	35.91%
Operating Margin	19.03%
EBIT Margin	19.03%
EBITDA Margin	24.60%
Pre-Tax Profit Margin	19.55%
Profit Margin	16.06%
Free Cash Flow	$468.90M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.72
Inventory Turnover	4.44
Receiveable Turnover	5.35
Days Sales in Receivables	68.20
Return on Equity	15.54%
Return on Tangible Equity	16.14%
Return on Assets	11.56%
Return on Investments	14.61%
Book Value Per Share	$44.11
Free Cash Flow per Share	$6.45
Operating Cash Flow per Share	$10.38

Data from Zacks Investment Research, Inc.